Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948551 | 1.00 | NR4A1 (0.54) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3948556 | 1.00 | NR4A1 (0.54) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL30924791 | 0.82 | NR4A1 (0.46) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3940538 | 0.81 | PTPN1 (0.50) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3940536 | 0.81 | PTPN1 (0.50) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3940539 | 0.81 | PTPN1 (0.50) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3939194 | 0.81 | NR4A1 (0.51) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL3939191 | 0.81 | NR4A1 (0.51) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL4087325 | 0.81 | NR4A1 (0.53) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL4087319 | 0.81 | NR4A1 (0.53) | NR4A1NR4A2NR4A3CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | NR4A1 93/4885NR4A2 672/4885NR4A3 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.